Joint Clinical Trials Office
A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men with Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 18, 2024
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Subjects with JAK Inhibitor-Naïve Myelofibrosis and Moderate Thrombocytopenia
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 26, 2024
The Pain Identification and Communication Toolkit: A Training Program to Support Family Caregivers of Persons with Alzheimer’s Disease and Related Dementias
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 13, 2024
An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 13, 2024
A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn’s Disease (Macaroni-23)
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 13, 2024
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 As Monotherapy In Subjects With Mature B-Cell Malignancies
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 13, 2024
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Safety and Efficacy Of Efruxifermin In Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 13, 2024
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 27, 2024
A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 29, 2024
A Two-Stage, Randomized, Controlled Trial Comparing the Safety and Efficacy of Iltamiocel with Placebo in the Treatment of Female Participants with Chronic Fecal Incontinence and a History of Obstetric Anal Sphincter Injury (DigniFI)
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 4, 2024